COVID-19 - September 24, 2020
SynAct Pharma initiates study for the treatment of ARDS in COVID-19 patients
SynAct Pharma has announced the initiation of a Phase II clinical study to evaluate the safety and efficacy of the company’s lead candidate drug AP1189 in adults diagnosed with COVID-19 and with early signs of Acute Respiratory Distress Syndrome (ARDS). The patients will be enrolled at medical centers in Brazil and in a collaboration between […]
COVID-19 - March 31, 2020
SynAct investigates AP1189 as additional therapy in hospitalized patients with COVID-19
SynAct Pharma investigates the possibility of developing its clinical anti-inflammatory lead candidate drug AP1189 as an additional therapy in hospitalized patients with COVID-19 infection, to prevent Acute Respiratory Distress Syndrome (ARDS). SynAct intends to explore the possibility of applying AP1189 to clinics through potential funding from government institutions and commercial partners operating in the COVID-19 […]
